Aoki Diabetes Research Institute Celebrating our 28th  year of research and improved outcomes.

 Copyright 2014  Aoki Diabetes Research Institute.   ALL RIGHTS RESERVED
Home About ADRI News MAT® TREATMENT Contact Us

  The Aoki Diabetes Research Institute (ADRI)  is a non-profit organization dedicated to research in the areas of diabetes and metabolism.  

    The main focus of our research is an unique type of  intravenous insulin therapy  called MAT®  treatment which  consists of  pulses of high dose insulin in a  program together with high doses of  oral glucose. This program safely provides much  higher doses of insulin to the tissues than can be achieved with subcutaneous insulin therapy.  This has a beneficial effect,  especially on  glucose metabolism in the liver, a site normally exposed to high insulin levels in persons who do not have diabetes.    

  The addition of MAT® treatments to a standard diabetes therapy regimen can reduce the number of hypoglycemic attacks (dangerously low blood sugar) by improving hypoglycemia awareness and can resolve, stabilize or delay many complications of diabetes such as kidney damage, damage to the retina of the eye, orthostatic hypotension (low blood pressure), foot ulcers, gastroparesis (slow emptying of the stomach) and painful neuropathy of the feet and legs.

In addition to the research program, ADRI has provided MAT® treatments as a clinical service for patients with unrelenting diabetic complications for most of the past twenty-seven years.  Besides improving or stabilizing diabetic complications, a program of weekly MAT®  treatments given over many years appears to prevent the onset of  additional complications.     

  Because MAT®  treatment requires a large investment of time and effort by the medical staff and the patient, this therapy is currently suggested only for patients with diabetes who have progressive diabetic complications despite following the American Diabetes Association  and American Association of Clinical Endocrinologists recommended treatment guidelines.